VINC · Vincerx Pharma, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $1.02M | - | $3.91M | $3.75M | $4.56M | - | $6.80M | $7.87M | $10.59M | - |
| SG&A | $2.32M | - | $3.88M | $3.61M | $2.92M | - | $3.52M | $3.79M | $4.51M | - |
| Total Operating Expenses | $3.33M | - | $7.79M | $7.37M | $7.48M | - | $10.32M | $11.66M | $15.10M | - |
| D&A | $0 | - | - | - | $13.0K | - | - | - | $13.0K | - |
| Operating Income | ($3.33M) | - | ($7.79M) | ($7.37M) | ($7.48M) | - | ($10.32M) | ($11.66M) | ($15.10M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($5.00M) | - | ($7.84M) | ($1.81M) | ($12.43M) | - | ($9.71M) | ($11.15M) | ($14.34M) | - |
| EPS - Basic | ($1.40) | - | ($3.40) | ($1.00) | ($11.60) | - | ($9.20) | ($10.40) | ($13.60) | - |
| EPS - Diluted | ($1.40) | - | ($3.40) | ($1.00) | ($11.60) | - | ($9.20) | ($10.40) | ($13.60) | - |
Balance Sheet
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.44M | $4.99M | $2.94M | $7.92M | $5.11M | $12.78M | $15.08M | $6.68M | $4.49M | $11.66M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $2.27M | $2.03M | $1.96M | $1.54M | $2.31M | $2.50M | $3.06M | $3.53M | $6.17M | $3.06M |
| Current Assets | $4.69M | $6.41M | $11.75M | $18.28M | $7.68M | $14.73M | $22.82M | $31.81M | $44.01M | $55.96M |
| Total Assets | $4.69M | $8.01M | $14.95M | $21.53M | $11.08M | $18.22M | $26.28M | $35.27M | $47.45M | $59.29M |
| Current Liabilities | $2.62M | $5.28M | $5.42M | $5.33M | $10.63M | $5.61M | $8.85M | $9.16M | $10.71M | $9.16M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $2.62M | $5.28M | $5.84M | $6.08M | $11.71M | $7.00M | $10.54M | $11.14M | $12.98M | $11.62M |
| Stockholders' Equity | $2.07M | $2.72M | $9.11M | $15.45M | ($622.0K) | $11.22M | $15.74M | $24.14M | $34.47M | $47.67M |
| Retained Earnings | ($194.19M) | ($189.19M) | ($181.19M) | ($173.35M) | ($171.54M) | ($159.11M) | ($156.54M) | ($146.83M) | ($135.68M) | ($121.34M) |
Cash Flow
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($4.45M) | - | - | - | ($7.74M) | - | - | - | ($13.09M) | - |
| Investing Cash Flow | - | - | - | - | $0 | - | - | - | $5.88M | - |
| Financing Cash Flow | $3.86M | - | - | - | $5.0K | - | - | - | $0 | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -106.7% | - | -52.5% | -8.4% | -112.1% | - | -37.0% | -31.6% | -30.2% | - |
| Return on equity | -242.0% | - | -86.1% | -11.7% | 1998.2% | - | -61.7% | -46.2% | -41.6% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.79 | 1.21 | 2.17 | 3.43 | 0.72 | 2.63 | 2.58 | 3.47 | 4.11 | 6.11 |
| Quick ratio | 1.79 | 1.21 | 2.17 | 3.43 | 0.72 | 2.63 | 2.58 | 3.47 | 4.11 | 6.11 |
| Cash ratio | 1.69 | 0.94 | 0.54 | 1.49 | 0.48 | 2.28 | 1.70 | 0.73 | 0.42 | 1.27 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 2.27 | 2.94 | 1.64 | 1.39 | -17.82 | 1.62 | 1.67 | 1.46 | 1.38 | 1.24 |
| Liabilities / Assets | 0.56 | 0.66 | 0.39 | 0.28 | 1.06 | 0.38 | 0.40 | 0.32 | 0.27 | 0.20 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.0x | - | 0.1x | 0.0x | - | - | 0.0x | 0.0x | 0.0x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 55.4% | - | 24.5% | 36.8% | 50.5% | - | 39.0% | 40.6% | 30.2% | - |
| Net income growth (YoY) | 59.8% | - | 19.3% | 83.8% | 13.3% | - | 42.4% | 39.5% | 12.7% | - |
| EPS growth (YoY) | 87.9% | - | 63.0% | 90.4% | 14.7% | - | -561.9% | -8566.7% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | -75.7% | -42.1% | -36.0% | - | -76.5% | -73.6% | -67.5% | -61.3% | -52.5% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Vincerx Pharma against the 5 most active filers in the same SIC group.